m+Medelevator.RU
← Поиск публикаций
ACS biomaterials science & engineering · 2026

Calcium-Specific-Binding PLGA Microspheres with Embedded BMP-2 for Bone Regeneration.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kim Minjae, Park Jun Ho, Choi Min-Ha, Lee Yan, Park Ji-Ung

Аннотация

Bone morphogenetic protein-2 (BMP-2) is a potent osteoinductive factor for bone regeneration, but its rapid clearance and dose-dependent adverse effects limit its clinical use. This study developed calcium-binding poly(butyl methacrylate-co-methacryloyloxyethyl phosphate) (PBMP)-coated poly(lactide-co-glycolide) (PLGA) microparticles to enhance calcium-rich surface anchoring and enable sustained BMP-2 release. Microparticles were characterized for morphology, zeta potential, encapsulation efficiency, release kinetics, and hydroxyapatite (HA)-binding affinity, and were further evaluated for in vivo efficacy. PBMP coating markedly increased the HA-binding affinity of PLGA microparticles. Encapsulation efficiency was over 55%, and BMP-2 was released in a sustained manner over 30 days, with the cumulative release gradually approaching a plateau during the later incubation period. When applied to a rat calvarial defect model, the PBMP-coated microparticle (BMP-2-PLGA/PBMP) group showed the greatest bone volume fraction, bone surface area, and trabecular number, along with the lowest trabecular separation compared to the free BMP-2 and control groups. Histological analysis confirmed denser and more mature bone matrix formation in the BMP-2-PLGA/PBMP group. These findings demonstrate that PBMP-coated PLGA microparticles provide HA-targeted, sustained BMP-2 delivery, resulting in improved bone regeneration and microarchitecture. This delivery platform represents a promising strategy for more effective bone defect repair.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты